Qinglin Tan

Qinglin Tan

Auto-generated profile, based on publicly available information

Qinglin Tan

Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people’s hospital), Dongguan, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JGJing Guo
Jing Guo
XZXuxian Zhong
Xuxian Zhong
QTQinglin Tan
Qinglin Tan
SYShengnan Yang
Shengnan Yang
JLJiaqi Liao
Jiaqi Liao
QZQiang Zuo
Qiang Zuo
Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive. Exploring the mechanisms and finding effective approaches to address trastuzumab resistance are of great necessity. Here, we confirmed that endoplasmic reticulum (ER) stress-induced trastuzumab resistance by up-regulating miR-301a-3p in HER2-positive GC cells. Moreover, we elucidated that miR-301a-3p mediated trastuzumab resistance by down-regulating the expression of leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) and subsequently activating the expression of insulin-like growth factor 1 receptor (IGF-1R) and fibroblast growth factor receptor 1 (FGFR1) under ER stress. We also found that intercellular transfer of miR-301a-3p by exosomes disseminated trastuzumab resistance. The present study demonstrated that exosomal miR-301a-3p could serve as a non-invasive biomarker for trastuzumab resistance, which was maybe a novel potential therapeutic target to overcome trastuzumab resistance and improve the curative effect of trastuzumab in HER2-positive GC patients.

1 January 2025 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
QTQinglin Tan
Qinglin Tan
PKPeiliang Kong
Peiliang Kong
GCGuobiao Chen
Guobiao Chen
CCChen Chen
Chen Chen
HMHuiting Mo
Huiting Mo
YWYifen Wu
Yifen Wu
Background: Lung adenocarcinoma (LUAD) is the most common lung cancer, associated with high metastasis and low survival rates. Identifying reliable biomarkers is essential for better prognosis and treatment. Methods: In this study, we analyzed RNA sequencing data, mutation information, and clinical data from the TCGA-LUAD cohort and other multicenter datasets to investigate the role of Holliday junction recognition protein (HJURP) in LUAD. We employed immunohistochemistry in tissue microarray cohort to validate the prognostic significance of HJURP. The DepMap project was used to validate the effect of HJURP knockout in vitro. Results: Holliday junction recognition protein was identified as an adverse prognostic factor in the TCGA-LUAD cohort and diverse ethnic groups. Its expression correlated with poor immunotherapy outcomes, and HJURP knockout suppressed cancer cell proliferation. High HJURP expression was linked to increased mutation frequency, particularly in TP53 and TTN. Pan-cancer analysis also indicated HJURP as a poor prognostic factor in various solid tumors. Conclusions: Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.